Taking into account these results, a clinical trial is evaluating the effect of a multi-peptide vaccine designed with several epitopes: EGFRvIII, IL-13, receptor alpha-2 (IL13Ralpha2), ephrin type A receptor 2 (EphA2), HER2/neu and YKL-40 peptides (167–170) in combination with TLR3 agonist poly-ICLC and Bevacizumab (a VEGF-blocking antibody) in recurrent GBM patients in a phase 2 trial (NCT02754362) (171). This evidence concerns the gene IL13 and glioblastoma.